# Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects

> **NCT02509104** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 56 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** FDC capsule of dutasteride and tamsulosin
- **DRUG:** Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet

## Key facts

- **NCT ID:** NCT02509104
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-30
- **Primary completion:** 2015-10-10
- **Final completion:** 2015-10-10
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2018-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02509104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02509104, "Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02509104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*